|Bid||49.00 x 1100|
|Ask||74.29 x 4000|
|Day's Range||70.33 - 73.64|
|52 Week Range||30.04 - 92.18|
|Beta (3Y Monthly)||1.19|
|PE Ratio (TTM)||142.27|
|Earnings Date||Mar 6, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.00|
Kim Popovits has been the CEO of Genomic Health, Inc. (NASDAQ:GHDX) since 2009. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
Cancer has long been a scourge of humankind and treatments and/or cures have always been iffy because every cancer, like every person, is different, observes Tony Daltorio, editor of Investors Alley's Growth Stock Advisor.
NEW YORK, Jan. 08, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Emergent (EBS) names Robert G. Kramer, Sr. as its next chief executive officer, who will assume office from Apr 1, 2019 onward. He will succeed the incumbent CEO Daniel J. Abdun-Nabi.
REDWOOD CITY, Calif., Jan. 7, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that, in collaboration with physicians around the world, it has delivered more than 1 million Oncotype DX® tests to cancer patients worldwide since it made its first test available to patients in 2004. To date, more than 53,000 physicians across 90 countries have used Oncotype DX to optimize treatment decisions for their breast, prostate and colon cancer patients. Use of Oncotype DX is helping deliver on the promise of precision medicine by improving outcomes for cancer patients around the world, while saving healthcare systems more than $5 billion globally to date.
Biogen (BIIB) commences enrollment in late-stage study to evaluate an expanded interval dosing of its MS drug, Tysabri, in patients with relapsing MS.
Vertex (VRTX) inks a collaboration deal with small biotech entity Arbor to discover novel proteins for progressing discovery of gene-editing therapies to tackle serious ailments.
The recent weakness in the NASDAQ that has sent the tech-heavy index into a bear market has created a buying opportunity. Gene therapy stocks are a perfect example. No matter what you feel is the cause of the current market pullback, I guarantee you it will not have any direct effect on the long-term success of the gene therapy stocks.
As a result of continued efforts to streamline operations, Integer Holdings (ITGR) has been registering strong profits over the last couple of quarters.
Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now expanding considerably in the international arena.
Genome sequencing - basically figuring out the order of DNA, the building blocks of life - was once essentially little more than a lab exercise. But now, it has reached commercial viability and then some. The field of genomics goes back to the 1950s, though it really started in earnest with the start of the Human Genome Project in 1990 - a 13-year, $2.7 billion enterprise that was completed in April 2013. Genome sequencing, in which scientists and their myriad machines detail the entire set of human DNA, has fantastic medical potential, allowing researchers to find genetic mutations - errors that can be harmless at times, but other times debilitating or even fatal. Moreover, genome sequencing is starting to reach realistic pricing - the costs have fallen down to about $1,000 at the low end, and companies are racing to cash in on the myriad opportunities. Here are six genome sequencing stocks to buy for this emerging medical technology. While genomics isn't the biggest investing buzzword today, this is a promising niche of the market that could take off as it gains more prominence. SEE ALSO: 19 Best Retirement Stocks to Buy in 2019
REDWOOD CITY, Calif., Dec. 19, 2018 /PRNewswire/ -- Genomic Health, Inc. (GHDX) today announced that the National Institute for Health and Care Excellence (NICE) in the United Kingdom has issued its updated guidance again recommending the Oncotype DX Breast Recurrence Score® test for use in clinical practice to guide adjuvant chemotherapy treatment decisions for certain patients with early-stage breast cancer. Further, NICE expanded its recommendation to include patients with micrometastases, indicating that some cancer cells have spread to the lymph nodes. "Oncotype DX is the only test that provides specific information about an individual patient's response to chemotherapy, correctly identifying the important minority of patients who will receive substantial treatment benefit and the majority of patients who will not benefit from chemotherapy," said Simon D H Holt, Honorary Consultant Surgical Oncologist, Peony Breast Care Unit at Prince Philip Hospital in Llanelli, UK.
Achillion's (ACHN) shares rise following the announcement of positive interim data from early to mid-stage studies evaluating its factor D inhibitors ??? ACH-4471, ACH-5228 and ACH-5548.
REDWOOD CITY, Calif. , Dec. 18, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that Kim Popovits , chairman of the board, chief executive officer and president, will present at ...
Insider Monkey finished processing more than 700 13F filings made by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of September 30th. What do these smart investors think about Genomic Health, Inc. (NASDAQ:GHDX)? Genomic Health, Inc. (NASDAQ:GHDX) has seen an increase in activity from the world’s largest hedge funds of […]
REDWOOD CITY, Calif. , Dec. 10, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple Oncotype DX Breast Recurrence Score ® (RS) presentations at the 2018 San Antonio ...
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HealthEquity's (HQY) impressive results in Q3 can be attributed to solid growth in HSA Members. Its bullish guidance for fiscal 2019 further raises investors' optimism on the stock.